- SIM0278 is a kind of Treg selective interleukin-2 mutation fusion protein (IL-2mu-Fc) which is about to enter the clinic, which can activate regulatory T cells (Treg) and is expected to be used in the treatment of various autoimmune diseases.
- Under the agreement, Almirall will be granted the exclusive right to develop and commercialize all indications of SIM0278 outside Greater China.
- Based on the possible outcomes of multiple indications, Voice will receive up to $492 million in total milestone payments from Almirall, including a down payment of $15 million.
Nanjing, ChinaSeptember 29, 2022On September 29th, 2022, 2096.HK and Almirall S.A. (BME: ALM), the world's leading biopharmaceutical company specializing in the treatment of skin diseases, announced that they had signed an exclusive licensing agreement for the autoimmune candidate IL-2 mutant fusion protein (IL-2 mu-Fc) SIM0278.
Almirall will be granted the exclusive right to develop and commercialize all indications of SIM0278 outside Greater China. Xiansheng Pharmaceutical Co., Ltd. will reserve all rights of SIM0278 in Greater China.
Under the terms of the agreement, Pioneer will receive a down payment of $15 million from Almirall and up to $492 million in development and commercial milestone payments (including some sales milestones) based on possible outcomes for multiple indications, as well as a low double-digit percentage cut based on future sales of the product in the agreed area.
Dr Tang Renhong, Co-Chief Executive Officer of Xiansheng Pharmaceutical Co-CEO, said: "I am very pleased to work with Almirall to carry out collaborative innovation in the treatment of autoimmune diseases. SIM0278, developed by its own protein engineering platform, is an important part of its' immune rebalance 'strategy in the field of autoimmune diseases. Xiansheng looks forward to working with partners to promote the global clinical validation of the project, so that more patients can use more effective drugs as soon as possible."
Dr Karl Ziegelbauer, chief scientific officer of Almirall, said:"Almirall attaches great importance to the expansion of R & D pipeline, so it chooses to reach a new development and commercial cooperation with Xiansheng Pharmaceutical Co., Ltd. SIM0278 has great potential for the treatment of a variety of autoimmune diseases and is expected to enrich our biomedical pipeline and further strengthen the company's edge in the field of dermatology. "